Mylan's Acquisition of Matrix
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BSTR279
Case Length : 20 Pages
Period : 2005-2007
Pub Date : 2008
Teaching Note :Not Available
Organization : Mylan, Inc./ Matrix Laboratories Ltd.
Industry : Pharmaceutical
Countries : USA; India; Global
To download Mylan's Acquisition of Matrix case study
(Case Code: BSTR279) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs.
400;
For delivery through courier (within India): Rs. 400 + Rs. 25 for Shipping & Handling Charges
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
|
<< Previous
Excerpts
Background Note
|
Mylan
Mylan was the second-largest US generic drug maker as of 2006. The company was
headquartered in West Virginia, USA, and was involved in developing, licensing,
manufacturing, marketing, and distributing many generic and proprietary drugs.
The company primarily focused on solid oral dosage generic drugs...
Matrix
Matrix, a listed Indian pharmaceutical company, was an API manufacturer
established in February 2001. It was the world's second-largest manufacturer of
APIs in terms of DMF filing. Its core business was to manufacture APIs and solid
oral dosage forms...
|
|
The Deal
In mid-2006, there were speculations that Mylan was in the
process of acquiring a majority stake in Matrix. Though the management at Matrix
denied the reports, there was a 10 percent rise in the company's share prices in
anticipation of the deal. These reports followed reports earlier in the year
that the world's largest generic drugs company Teva was interested in acquiring
Matrix...
|
|
Rationale Behind the Acquisition
Benefits for Mylan
Mylan acquired the majority stake in Matrix primarily to establish a
global distribution network for its generic drug portfolio. This
acquisition acted as an entry window for Mylan to tap the huge potential
of emerging pharmaceutical markets such as India, China, and Africa,
where Matrix already had a significant presence through its various
strategic alliances...
Benefits for Matrix
The Mylan Matrix merger was expected to benefit Matrix as well. |
Experts felt that the merger would help in accelerating
Matrix's expansion plans in India and abroad. As a part of Mylan, Matrix would
benefit from Mylan's predominant presence in the US and their combined expanded
production capabilities and manufacturing capacity, which would result in
economies of scale...
Excerpts Contd...>>
|
